180 Wealth Advisors LLC Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)

180 Wealth Advisors LLC increased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 60.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 32,447 shares of the life sciences company's stock after buying an additional 12,279 shares during the period. 180 Wealth Advisors LLC's holdings in Illumina were worth $2,574,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Partnership Wealth Management LLC lifted its stake in Illumina by 4.7% in the 1st quarter. Partnership Wealth Management LLC now owns 8,472 shares of the life sciences company's stock worth $672,000 after purchasing an additional 377 shares in the last quarter. GAMMA Investing LLC lifted its stake in Illumina by 2,009.1% in the 1st quarter. GAMMA Investing LLC now owns 65,297 shares of the life sciences company's stock worth $51,810,000 after purchasing an additional 62,201 shares in the last quarter. 111 Capital purchased a new stake in Illumina in the 4th quarter worth $223,000. Wealth Enhancement Advisory Services LLC lifted its stake in Illumina by 13.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 20,197 shares of the life sciences company's stock worth $2,699,000 after purchasing an additional 2,421 shares in the last quarter. Finally, PKO Investment Management Joint Stock Co purchased a new stake in Illumina in the 4th quarter worth $200,000. Institutional investors own 89.42% of the company's stock.

Insider Activity at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the transaction, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.60% of the stock is currently owned by corporate insiders.

Illumina Stock Up 0.6%

Shares of NASDAQ ILMN traded up $0.48 during midday trading on Thursday, reaching $83.64. 586,155 shares of the company's stock traded hands, compared to its average volume of 2,410,718. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock's 50 day simple moving average is $77.75 and its 200-day simple moving average is $105.41. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a market cap of $13.24 billion, a price-to-earnings ratio of -10.89, a P/E/G ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period last year, the firm earned $0.98 earnings per share. The company's quarterly revenue was down 1.4% on a year-over-year basis. On average, analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of several recent research reports. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Stephens restated an "overweight" rating and set a $105.00 target price on shares of Illumina in a research report on Tuesday, May 20th. Barclays decreased their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday, April 10th. Canaccord Genuity Group decreased their target price on shares of Illumina from $92.00 to $87.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Finally, Robert W. Baird decreased their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Illumina presently has an average rating of "Moderate Buy" and a consensus price target of $128.84.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.